AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion.
The deal includes upfront payment plus development milestones.
Bretisilocin, a short-acting serotonin (5-HT)2A receptor agonist and 5-HT releaser, is currently in Phase 2 development